Online citations, reference lists, and bibliographies.

An Orthotopic Implantation Mouse Model Of Human Malignant Pleural Mesothelioma For In Vivo Photon Counting Analysis And Evaluation Of The Effect Of S-1 Therapy.

K. Yanagihara, M. Tsumuraya, M. Takigahira, K. Mihara, T. Kubo, K. Ohuchi, T. Seyama
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Human malignant pleural mesothelioma (HMPM) is an aggressive neoplasm that is highly resistant to conventional therapies. We established 3 HMPM cell lines (TCC-MESO-1, TCC-MESO-2 and TCC-MESO-3) from Japanese patients; the first 2 from the primary and metastatic tumors of a patient with the epithelioid type of HMPM, and the third from a patient with biphasic characteristics of the tumor (epithelioid and sarcomatous phenotypes). The 3 cell lines resembled the original HMPMs in their morphological and biological features, including the genetic alterations such as lack of p16 expression and mutation of p53. Their tumorigenicity was determined in SCID mice by orthotopic implantation (20-46%). The tumorigenicity of the HMPM cell lines, which was relatively low, was enhanced by repeated subcultures and orthotopic implantations, and 3 competent tumorigenic sublines were produced (Me1Tu, Me2Tu and Me3Tu sublines from the TCC-MESO-1, TCC-MESO-2 and TCC-MESO-3 cell lines, respectively). The resultant HMPM sublines efficiently generated tumors in the SCID mice (100%) following orthotopic implantation. SCID mice implanted with the competent sublines, into one of which the luciferase gene was introduced, displayed quantitative fluctuation of the bioluminescence for the tumor volume in vivo. Oral administration of S-1, an anticancer agent, suppressed the proliferation of the luciferase gene-expressing Me1Tu subline in the mouse models in vivo, with a treated-to-control ratio of the mean tumor volume of 0.2. The orthotopic implantation mouse model proved to be useful for quantitative evaluation of the efficacy of novel anticancer drugs and also for studying the biology of HMPMs in vivo.
This paper references
10.1073/PNAS.0501753102
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.
F. Takeshita (2005)
10.1378/chest.100.2.429
Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4).
N. Masuda (1991)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1111/j.1440-1827.1995.tb03399.x
Establishment and characterization of a new human mesothelioma cell line (T-85) from malignant peritoneal mesothelioma with remarkable thrombocytosis.
T. Tange (1995)
Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract.
K. Yanagihara (1993)
Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
M. Kobayashi (2008)
10.1158/0008-5472.CAN-05-3259
A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination.
K. Yanagihara (2006)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1111/j.1349-7006.2008.00896.x
Establishment and molecular profiling of a novel human pancreatic cancer panel for 5‐FU
K. Yanagihara (2008)
10.1080/08958370600835393
Animal Models of Malignant Mesothelioma
A. Kane (2006)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1158/1078-0432.CCR-06-1056
Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma
E. P. Spugnini (2006)
10.1080/01913120500313192
The Role of Analytical SEM in the Determination of Causation in Malignant Mesothelioma
V. Roggli (2006)
10.1111/j.1349-7006.2004.tb02489.x
Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice
K. Yanagihara (2004)
10.1002/IJC.21340
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
T. Arao (2006)
10.1038/nrc1717
The multiple uses of fluorescent proteins to visualize cancer in vivo
R. Hoffman (2005)
10.1089/hum.2008.036
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
K. Kelly (2008)
10.1007/s00418-004-0701-1
Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis
M. Philippeaux (2004)
10.3892/IJO.25.6.1531
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
M. Nukatsuka (2004)
10.1016/S0959-8049(02)00048-5
Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
T. Takechi (2002)
10.1016/j.canlet.2008.02.018
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
H. Ogino (2008)
10.1016/S0016-5085(00)70255-1
Integrin α6β4 as a suppressor and a predictive marker for peritoneal dissemination in human gastric cancer
Yoshiyuki Ishii (2000)
10.1038/sj.bjc.6693248
Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells
F. Pimpec-Barthes (1999)
10.1038/SJ.NEO.7900079
Use of reporter genes for optical measurements of neoplastic disease in vivo.
C. Contag (2000)
Cytology of experimental mesotheliomas induced with crocidolite asbestos.
J. Topov (1987)
10.1007/s00280-006-0265-y
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
A. Zhu (2006)
10.1158/0008-5472.CAN-05-2312
A mouse model recapitulating molecular features of human mesothelioma.
D. Altomare (2005)
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
T. Shirasaka (1996)
10.1016/j.bbrc.2008.02.114
MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
T. Segawa (2008)
10.1158/1078-0432.CCR-08-0255
Enhanced Antitumor Therapy by Inhibition of p21waf1 in Human Malignant Mesothelioma
R. Lazzarini (2008)
10.1002/ijc.23452
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
J. Littlejohn (2008)
Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model.
H. Colt (1996)
10.3892/or.1.3.507
Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions.
A. Yokoyama (1994)
10.1158/1078-0432.CCR-07-1388
Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts
P. Bertino (2008)
10.1158/1078-0432.CCR-08-3236
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene
P. Brader (2009)
10.3727/000000006783981062
Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
Nobutaka Edakuni (2006)
10.1111/j.1749-0774.2003.tb00157.x
Establishment and characterization of a human malignant mesothelioma cell line (HMMME)
I. Ishiwata (2011)
10.1111/j.1349-7006.2003.tb01361.x
Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)‐tagged human gastric cancer cell line
H. Nakanishi (2003)
10.1111/j.1349-7006.2006.00184.x
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients
N. Usami (2006)
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
J. Cheng (1994)
10.1016/j.ccr.2008.01.030
A conditional mouse model for malignant mesothelioma.
J. Jongsma (2008)
10.1158/0008-5472.CAN-08-2822
Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
T. Nakajima (2008)
10.1002/1097-0142(19910801)68:3<558::AID-CNCR2820680319>3.0.CO;2-I
Usefulness of the nude mouse model in mesothelioma based on a direct patient–xenograft comparison
A. Philippe Chahinian (1991)
10.1016/0003-4975(95)00045-M
Characteristics of nine newly derived mesothelioma cell lines.
H. Pass (1995)
10.1111/j.1349-7006.2006.00163.x
Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES‐10 cells) highly expressing vascular endothelial growth factor and its receptor
E. Nakataki (2006)
10.1111/j.1349-7006.2005.00054.x
Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer
K. Yanagihara (2005)
10.1111/j.1440-1827.2009.02344.x
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
K. Ishikawa (2009)
10.3892/IJO.13.4.693
Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
M. Fukushima (1998)
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
R. A. Metcalf (1992)
10.3816/CLC.2009.n.014
Malignant pleural mesothelioma: medical treatment update.
Daniel A. Vorobiof (2009)
10.1186/1471-2407-6-130
Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis
D. Martarelli (2005)
10.1378/CHEST.113.1_SUPPLEMENT.61S
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)



This paper is referenced by
10.1080/01635581.2013.776089
Inhibitory Effects of Isoflavones on Tumor Growth and Cachexia in Newly Established Cachectic Mouse Models Carrying Human Stomach Cancers
K. Yanagihara (2013)
10.1111/j.1349-7006.2010.01827.x
Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma
A. Sato (2011)
10.3389/fphar.2018.01129
Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells
Yuzo Sato (2018)
10.18632/oncotarget.26367
Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma
Kazuyoshi Yanagihara (2018)
10.2217/LMT.14.27
Mouse models of mesothelioma: strengths, limitations and clinical translation
C. Robinson (2014)
10.3389/fgene.2018.00232
Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts
Noushin Nabavi (2018)
10.1111/j.1440-1843.2010.01890.x
Translational advances in pleural malignancies.
Georgios T. Stathopoulos (2011)
10.1111/cas.12005
Multi‐walled carbon nanotubes translocate into the pleural cavity and induce visceral mesothelial proliferation in rats
J. Xu (2012)
10.1007/978-3-030-16884-1_6
Preclinical Models in Mesothelioma
Ilaria Fuso Nerini (2019)
10.1089/hum.2008.036
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
K. Kelly (2008)
10.7150/JCA.2.123
In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice
M. Feng (2011)
10.2220/BIOMEDRES.34.13
Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma.
Houman Goudarzi (2013)
10.1016/j.canlet.2013.07.020
Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway.
Houman Goudarzi (2013)
Semantic Scholar Logo Some data provided by SemanticScholar